Commercialization of a phylogenetic cell separation method for downstream purification of nucleic acids
Active Project Grant Awarded Last action
- Award ID
- R42GM140530
- Recipient
-
Syracuse Biolabs, Inc. UEI QAW2G2NJY562
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,556,002
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 88% complete
- Place of performance
- Syracuse, NY 13244, USA
Award details come from USAspending.gov.
Description
- Abstract
- The success of all microbiome-based studies is highly dependent on effective sample purification of the target organisms of interest. Characterizing individual organismal components of these metagenomic samples relies heavily upon the ability to separate the individual phylogenetic components, such as removing human cells from the microbiological fraction while preventing sample loss or degradation. This phase II sttr project aims to continue the development of and commercialize a patent pending simple and inexpensive purification approach aimed at effectively separating and preserving host and microbial DNA from a metagenomic sample. This method will ensure all organismal DNA is preserved (i.e., not "sacrificed" or lost) during initial separation steps, unlike protocols employed by existing DNA purification kit manufacturers. Outcomes result in higher quality DNA sequence data (i.e., higher sequencing coverage and higher sensitivity), thus providing robust information content, leading to higher confidence in organismal characterization. Syracuse biolabs, INC. (SBL), has teamed with scientists in the forensic and national security sciences institute (fnssi) at syracuse university to further improve and commercialize this novel DNA purification approach. The phase i project clearly demonstrated the superiority of the syracuse method to currently available kits from qiagen and zymo research. This phase II project has five aims directed toward continued development of the method into a commercial product for fieldable cell/DNA purification modules of metagenomic samples. Our metagenomic DNA purification kit is also applicable to fields outside of the human microbiome research market, including forensic identification and geolocation of biological samples relevant to criminal and intelligence related activities, DNA based ecological research, plant and microbial based geosourcing, and defense/homeland security efforts (requiring DNA purification from environmental samples).
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $534,278 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $510,862 | |
| Original award | $510,862 |
Quick answers
Who received award R42GM140530?
R42GM140530 was awarded to Syracuse Biolabs, Inc. by National Institute of General Medical Sciences (National Institutes of Health) on September 15, 2021.
How much is award R42GM140530 worth?
$1,556,002 has been obligated on R42GM140530.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award